Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by GenSight Biologics S.A.
GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation
December 18, 2024
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France
November 13, 2024
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ®
October 28, 2024
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update
October 24, 2024
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates
September 23, 2024
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update
July 23, 2024
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates
June 20, 2024
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
April 04, 2024
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results
March 22, 2024
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024
March 12, 2024
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024
March 06, 2024
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023
March 15, 2023
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial
March 13, 2023
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology
March 09, 2023
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology
May 19, 2022
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy
January 24, 2022
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial
December 14, 2021
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
November 30, 2021
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Announces the Publication of a Review of Gene Therapy Trials for LHON in International Ophthalmology Clinics
October 06, 2021
From
GenSight Biologics S.A.
Via
Business Wire
GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials
September 09, 2021
From
GenSight Biologics S.A.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.